Nuvectis Pharma, Inc. (NVCT) Dividend History

Company News

• Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

  Nuvectis Pharma, a clinical-stage biopharmaceutical company, announced the pricing of its $13.5 million public offering of 2.7 million shares of common stock at $5 per share. The company plans to use the proceeds to advance the development of its drug candidates NXP800 and NXP900.

  GlobeNewswire Inc.
• Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

  Nuvectis Pharma, Inc. reported its Q3 2024 financial results and provided updates on the development of its drug candidates NXP800 and NXP900. The company expects a clinical data update for NXP800 this month and has progressed the NXP900 Phase 1a study with no dose-limiting toxicities.

  GlobeNewswire Inc.
• Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

  Nuvectis Pharma announced that the FDA granted Orphan Drug Designation for its drug candidate NXP800 to treat a subset of ovarian cancer with ARID1a deficiency. This designation provides financial incentives and potential marketing exclusivity if the drug is approved.

  GlobeNewswire Inc.
• Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

  The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  Zacks Investment Research
• Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

  Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.

  GlobeNewswire Inc.